Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.
Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.
Transcript
When there are successful pilots in delivering value-based care, how well does the United States health system scale these pilots across country?
There have been many pilots in terms of attempting to sort of incorporate value into cared delivery, which of course I would define as better aligning the way care is provided with the payment system. To answer the question, I don’t think we’ve really gotten to scale yet. I think these have remained pilots. I think, probably, the scale that’s happened has happened within organizations and scaling across organizations, so taking programs that they’ve done and branching them out into multiple ambulatory clinics or other acute care hospitals or integrating across their system. I think less so, broadly speaking, across the market or across the country.
You know, that’s not to say that there aren’t some examples. But, I think one of the big barriers frankly, and as was talked about in this meeting is, that we’re still largely in a discounted fee for service-based payment arrangement, so there really isn’t the incentive to scale these things as much as maybe some people had hoped. I think a lot of the organizations that are doing work in this, the delivery systems that are doing work, are ones that are making a bet, forward thinking, that this is the way the payment landscape is really going to go and that its worth going down this path. In fact, I’ve talked to some who have said, “we know what we’re doing is losing money or at least not covering the investment that were making, but we believe that it’s worth kind of getting experience with these programs now, these pilots now, because it will pay off in the future.”
So again, to go back to the question, I don’t think we’ve had nearly the level of scale that was envisioned by CMS, by many others, as we talked about expectations for value-based payment models. It’s sort of that thing that everybody seems to be involved in, but it hasn’t grown quite at the rate that we expected it to be.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More